482,055 Shares in Zimmer Biomet Holdings, Inc. $ZBH Bought by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 482,055 shares of the medical equipment provider’s stock, valued at approximately $41,500,000.

Several other large investors have also made changes to their positions in ZBH. DV Equities LLC bought a new position in shares of Zimmer Biomet in the fourth quarter worth about $25,000. Monetary Solutions Ltd purchased a new position in Zimmer Biomet in the 4th quarter worth approximately $30,000. Gen Wealth Partners Inc bought a new position in Zimmer Biomet in the 4th quarter worth approximately $31,000. Elevation Wealth Partners LLC grew its holdings in Zimmer Biomet by 145.9% during the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 229 shares in the last quarter. Finally, Cornerstone Financial Management LLC purchased a new stake in Zimmer Biomet during the 4th quarter valued at approximately $37,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $100.65 on Thursday. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The firm’s fifty day moving average is $92.16 and its 200 day moving average is $90.85. The company has a market cap of $19.20 billion, a price-to-earnings ratio of 24.49, a PEG ratio of 2.70 and a beta of 0.45.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. During the same period last year, the company posted $2.07 EPS. The business’s revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.53 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, June 25th were issued a $0.24 dividend. The ex-dividend date was Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s payout ratio is 23.36%.

Insider Buying and Selling at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the sale, the insider owned 27,251 shares in the company, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.28% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on ZBH. Sanford C. Bernstein boosted their target price on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a report on Thursday, August 6th. UBS Group reiterated a “buy” rating and issued a $120.00 price target on shares of Zimmer Biomet in a report on Thursday, August 6th. Weiss Ratings upgraded shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, August 4th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Finally, Stifel Nicolaus raised their price objective on Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and an average price target of $104.42.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.